JP2003519661A5 - - Google Patents

Download PDF

Info

Publication number
JP2003519661A5
JP2003519661A5 JP2001551483A JP2001551483A JP2003519661A5 JP 2003519661 A5 JP2003519661 A5 JP 2003519661A5 JP 2001551483 A JP2001551483 A JP 2001551483A JP 2001551483 A JP2001551483 A JP 2001551483A JP 2003519661 A5 JP2003519661 A5 JP 2003519661A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001551483A
Other languages
Japanese (ja)
Other versions
JP2003519661A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2000/033844 external-priority patent/WO2001051059A1/en
Publication of JP2003519661A publication Critical patent/JP2003519661A/ja
Publication of JP2003519661A5 publication Critical patent/JP2003519661A5/ja
Withdrawn legal-status Critical Current

Links

JP2001551483A 2000-01-11 2000-12-15 クラリスロマイシンの多形の製造方法 Withdrawn JP2003519661A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17547700P 2000-01-11 2000-01-11
US60/175,477 2000-01-11
PCT/US2000/033844 WO2001051059A1 (en) 2000-01-11 2000-12-15 Processes for preparing clarithromycin polymorphs

Publications (2)

Publication Number Publication Date
JP2003519661A JP2003519661A (ja) 2003-06-24
JP2003519661A5 true JP2003519661A5 (https=) 2005-12-22

Family

ID=22640371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001551483A Withdrawn JP2003519661A (ja) 2000-01-11 2000-12-15 クラリスロマイシンの多形の製造方法

Country Status (22)

Country Link
US (2) US6624292B2 (https=)
EP (1) EP1280535B1 (https=)
JP (1) JP2003519661A (https=)
KR (1) KR20020071012A (https=)
CN (1) CN1450903A (https=)
AT (1) ATE288758T1 (https=)
AU (2) AU2261901A (https=)
BR (1) BR0016992A (https=)
CA (1) CA2397092A1 (https=)
DE (1) DE60018119T2 (https=)
DK (1) DK1280535T3 (https=)
ES (1) ES2236023T3 (https=)
HR (1) HRP20020572A2 (https=)
HU (1) HUP0204252A3 (https=)
IL (1) IL150698A0 (https=)
IS (1) IS6463A (https=)
PL (1) PL356645A1 (https=)
PT (1) PT1280535E (https=)
RU (1) RU2002118308A (https=)
SI (1) SI1280535T1 (https=)
WO (1) WO2001051059A1 (https=)
ZA (1) ZA200205229B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001044262A1 (en) * 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
AU2261901A (en) * 2000-01-11 2001-07-24 Teva Pharma Processes for preparing clarithromycin polymorphs
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
KR20030047873A (ko) * 2000-02-29 2003-06-18 테바 파마슈티컬 인더스트리즈 리미티드 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물
AU2001263812B2 (en) * 2000-03-28 2004-09-23 Sandoz Ag Granulated particles with masked taste
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
SI1285659T1 (sl) * 2001-08-13 2008-02-29 Fond Salvatore Maugeri Clinica Uporaba klaritromicinskih sestavkov za pripravo zdravila za zdravljenje deformirajocega artritisa
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
AU2004258949B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258953B2 (en) * 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2535177A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2005061524A2 (en) * 2003-12-22 2005-07-07 Ranbaxy Laboratories Limited Process for the preparation of form ii clarithromycin
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
EP1715971A4 (en) * 2004-01-28 2010-10-13 Cytimmune Sciences Inc FUNCTIONALIZED COLLOIDAL METAL COMPOSITIONS AND METHODS
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
CA2572292A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
JP2009500356A (ja) * 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
WO2007064595A2 (en) * 2005-11-29 2007-06-07 Bausch & Lomb Incorporated Fluocinolone acetonide drug substance polymorphic interconversion
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
CA2773037A1 (en) * 2009-09-02 2011-03-10 Bernard Charles Sherman Clarithromycin extended-release tablet
MY180626A (en) 2013-11-15 2020-12-03 Akebia Therapeutics Inc Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473525A1 (fr) 1980-01-11 1981-07-17 Roussel Uclaf Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments
US4331803A (en) 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS60214796A (ja) 1984-04-06 1985-10-28 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシン類の製法
JPS61103890A (ja) 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd 6−0−メチルエリスロマイシンa誘導体
US4670549A (en) 1985-03-18 1987-06-02 Taisho Pharmaceutical Co., Ltd. Method for selective methylation of erythromycin a derivatives
US4640910A (en) 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4672056A (en) 1985-11-12 1987-06-09 Abbott Laboratories Erythromycin A derivatives and method of use
KR960000434B1 (ko) 1986-12-17 1996-01-06 다이쇼 세이야꾸 가부시끼가이샤 에리스로마이신 a유도체 및 그의 제조 방법
GB8721165D0 (en) 1987-09-09 1987-10-14 Beecham Group Plc Chemical compounds
JP2751385B2 (ja) 1988-05-19 1998-05-18 大正製薬株式会社 エリスロマイシンaオキシム及びその塩の製造方法
US5440505A (en) * 1994-01-21 1995-08-08 Intel Corporation Method and circuitry for storing discrete amounts of charge in a single memory element
US5756473A (en) 1995-11-21 1998-05-26 Abbott Laboratories 6-O-methyl erythromycin D and process for making
US5872229A (en) 1995-11-21 1999-02-16 Abbott Laboratories Process for 6-O-alkylation of erythromycin derivatives
US5719272A (en) 1996-04-02 1998-02-17 Abbott Laboratories 2'-protected 3'-dimethylamine, 9-etheroxime erythromycin A derivatives
US5837829A (en) 1996-04-02 1998-11-17 Abbott Laboratories 9-oximesilyl erythromycin a derivatives
US5808017A (en) 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
US5844105A (en) 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5858986A (en) 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
DE69730138T2 (de) 1996-07-29 2005-03-03 Abbott Laboratories, Abbott Park Herstellung von kristallinen form ii von clarithromycin
US5945405A (en) 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US5864023A (en) 1997-02-13 1999-01-26 Abbott Laboratories 3'-N'oxide, 3'-n-dimethylamine, 9-oxime erythromycin a derivatives
US5852180A (en) 1997-11-17 1998-12-22 Abbott Laboratories Chemical synthesis of 6-O-alkyl erythromycin A
US5932710A (en) 1997-12-01 1999-08-03 Abbott Laboratories Process for preparing 6-O-alkyl-9-oxime erythromycin B
US5892008A (en) 1997-12-16 1999-04-06 Abbott Laboratories Process for the preparation of 6-O-methyl erythromycin a using 9-hydroxy erythromycin derivatives
KR100377159B1 (ko) * 1998-09-09 2003-08-19 한미약품공업 주식회사 잔류 용매가 없는 클라리스로마이신의 결정형 2의 제조 방법
WO2001044262A1 (en) * 1999-12-16 2001-06-21 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs and novel polymorph iv
AU2261901A (en) * 2000-01-11 2001-07-24 Teva Pharma Processes for preparing clarithromycin polymorphs
KR20030047873A (ko) * 2000-02-29 2003-06-18 테바 파마슈티컬 인더스트리즈 리미티드 클라리트로마이신 및 클라리트로마이신 중간체의 제조방법, 실질적으로는 옥심이 제거된 클라리트로마이신 및이를 포함하는 약학적 조성물

Similar Documents

Publication Publication Date Title
BE2017C009I2 (https=)
BE2016C059I2 (https=)
BE2009C057I2 (https=)
BE2010C019I2 (https=)
BE2011C041I2 (https=)
JP2002021687A5 (https=)
JP2002091654A5 (https=)
CN3138718S (https=)
CN3141017S (https=)
AU2000276891A8 (https=)
AU2000274567A8 (https=)
AU2000273097A8 (https=)
AU2000270908A8 (https=)
AU2000270757A8 (https=)
BY4905C1 (https=)
BY5592C1 (https=)
CL45687B (https=)
CN3135469S (https=)
CN3135584S (https=)
CN3135930S (https=)
CN3136721S (https=)
CN3137472S (https=)
CN3138061S (https=)
AU2000256911A8 (https=)
CN3139849S (https=)